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Abstract
Background: Toll-like receptors (TLRs) are crucial for recognition of pathogen-associated molecular patterns by cells
of the innate immune system. TLRs are present and functional in CD4
+ T cells. Memory CD4
+ T cells, predominantly
central memory cells (TCM), constitute the main reservoir of latent HIV-1. However, how TLR ligands affect the
quiescence of latent HIV within central memory CD4
+ T cells has not been studied.
Results: We evaluated the ability of a broad panel of TLR agonists to reactivate latent HIV-1. The TLR-1/2 agonist
Pam3CSK4 leads to viral reactivation of quiescent HIV in a model of latency based on cultured TCM and in resting CD4
+
T cells isolated from aviremic patients. In addition, we investigated the signaling pathway associated with Pam3CSK4
involved in HIV-1 reactivation. We show that the transcription factors NFκB, NFAT and AP-1 cooperate to induce viral
reactivation downstream of TLR-1/2 stimulation. Furthermore, increasing levels of cyclin T1 is not required for
TLR-mediated viral reactivation, but induction of viral expression requires activated pTEFb. Finally, Pam3CSK4 reactivates
latent HIV-1 in the absence of T cell activation or proliferation, in contrast to antigen stimulation.
Conclusions: Our findings suggest that the signaling through TLR-1/2 pathway via Pam3CSK4 or other reagents should
be explored as an anti-latency strategy either alone or in combination with other anti-latency drugs.
Background
The existence of latent reservoirs of HIV-infected cells
constitutes the major impediment towards viral eradica-
tion. Latent infection is associated with undetectable levels
of viral gene expression and appears to be non-cytopathic.
However, upon reactivation, latent viruses enter an active
mode of replication in which they are fully competent for
spread and induction of disease [1-3]. The main latent
reservoir is known to reside within the subset of CD4
+
memory T cells [1-5]. The current thinking in the field
is that a combination of agents that disrupt latency
(“anti-latency” drugs), when given with continuous anti-
retroviral therapy (ART), may be an effective approach to-
ward viral eradication [6-8].
Transient bursts or “blips” of HIV-1 replication occur
even in patients whose virus is well suppressed by anti-
retroviral therapy (ART) [9]. The origin of viral “blips” is
not known. Several factors can contribute to these viral
blips, such as selection of drug resistant variants, antigen-
driven target cell activation, vaccination, opportunistic
infections or random variation of test measurements [10].
Interestingly, several vaccination regimens [11-14] and
pathogen infections [15-19] have been shown to transi-
ently increase the levels of plasma RNA in HIV-1 infected
patients even in the presence of ART. Therefore, it is
tempting to speculate that exposure to microbial products
may trigger reactivation of latent viruses and thus influ-
ence the size of the latent reservoir.
Pathogen infections are primarily sensed by the innate
immune system through the interaction of conserved mo-
lecular structures named pathogen-associated molecular
patterns (PAMPs) via host-encoded pattern recognition re-
ceptors (PRRs) [20,21]. PRRs are germline-encoded recep-
tors that recognize several classes of molecules typical of
pathogens, such as proteins, lipids, carbohydrates and nu-
cleic acids [21]. Among PRRs, Toll-like receptors (TLRs)
are the most widely studied. TLR-1, 2, 4, 5, 6 and 10 are
present on the cell surface and recognize PAMPs derived
from bacteria, fungi and protozoa. Whereas, TLR-3, 7,
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recognize mainly nucleic acids derived from bacteria
and viruses [21,22]. TLRs have been detected on cells
of both the innate and adaptive immune system (such us
dendritic cells, macrophages, granulocytes, T cells, B cells,
NK cells and mast cells) as well as endothelial and epithe-
lial cells [23].
However, little is known about whether and how TLR
ligands affect the latent reservoir of HIV infection in
central memory CD4
+ T cells. We have analyzed the po-
tential ability of TLR agonists to transactivate the HIV-1
LTR using a previously described method for the gener-
ation of latently infected central memory T cells (TCM)
[24,25]. We demonstrate that Pam3CSK4, a TLR-1/2
agonist, is able to reactivate latent HIV-1 in this in vitro
model and in cells isolated from aviremic patients. This re-
activation is NFκB, NFAT and AP-1-mediated and require
pTEFb activity. This pathway differs from that initiated by
T cell receptor engagement, which was shown to be medi-
ated, in the same latency model, primarily by NFAT [24].
Importantly from the standpoint of therapeutic applica-
tions, Pam3CSK4-induced viral reactivation is achieved in
the absence of T cell activation and proliferation. There-
fore, the signaling pathway activated by Pam3CSK4 ap-
pears to be selective for latent, integrated viruses and
represents an attractive therapeutic target that can be
exploited in eradication strategies.
Results
Pam3CSK4, a TLR-1/2 agonist, reactivates latent HIV-1
in cultured TCM cells
We explored whether TLR agonists could reactivate latent
HIV-1 using cultured TCM as model of latency [24,25]. We
used representative agonists for the different TLR recep-
tors such as triacylated synthetic lipopeptide Pam3CSK4, a
TLR-1/2 agonist; diacylated synthetic lipopeptide (FSL-1),
a known TLR-2/6 agonist; the synthetic analog of double-
stranded RNA (Poly(I:C)), recognized by TLR-3; lipo-
polysaccharide (LPS), the principal component of Gram
negative bacteria that activates TLR-4; flagellin, a potent
stimulator of TLR-5; imiquimod, an analog to guanosine
that specifically activates TLR-7; ssRNA40, a GU-rich
single-stranded RNA oligonucleotide also known as
R-1075, recognized by TLR-7/8 [26] and ODN2006, an
unmethylated CpG dinucleotide and activator of TLR-9.
As shown in Figure 1A, the triacylated lipopeptide and
TLR-1/2 agonist Pam3CSK4 was able to efficiently reacti-
vate latent HIV in latently infected cultured TCM gener-
ated from 5 different donors. No other TLR agonist
tested had activity above background. In order to verify
that the above agonists were biologically active at the
concentrations used, we performed four additional tests.
First, we tested the above TLR agonists in their ability to
reactivate latent HIV-1 in three other models of latency.
Second, we tested their ability to induce IL-8 production
in the promonocytic cell line THP-1 [27]. As shown in
Additional file 1: Figure S1A, Flagellin was able to reacti-
vate latent HIV-1 in the J-Lat clone 10.6 as previously de-
scribed [28]. Even though the TLR-2/6 agonist Pam2CSK4
and the TLR-4 agonist LPS were unable to reactivate
latent HIV-1 in cultured TCM, both were able to induce a
strong IL-8 response in THP-1 cells (Additional file 1:
Figure S1B). The TLR7 agonist imiquimod was able to re-
activate latent HIV-1 in the T cell line ACH2 (Additional
file 1: Figure S1D). Finally, the TLR-9 agonist ODN2006
was able to reactivate latent HIV-1 in the cell lines U1 and
ACH2 (Additional file 1: Figure S1C and D) [29]. Neither
the TLR-3 nor the TLR-8 agonist had activity in any of our
experimental systems. We do not disregard the possibility
that these TLRs may reactivate latent viruses.
TLR-2 recognizes a variety of molecular patterns from
viruses, bacteria, fungi and protozoa [21]. The specificity of
PAMP recognition by TLR-2 is somewhat broad because
TLR-2 can form functional homodimers, as well as hetero-
dimers with TLR-1, TLR-6, TLR-10 or Dectin-1 [30-33].
To test which TLR-2 homo or heterodimers are capable of
reactivating latent viruses in cultured TCM cells, we incu-
bated latently infected cells with ligands for TLR-2 that use
different co-receptors. We tested the synthetic diacylated
lipopeptide Pam2CSK4 and the N-terminal part of the dia-
cylated lipoprotein derived from Mycoplasma salivarium,
FSL-1, both of which have been shown to induce signaling
through a TLR-2/6 complex [34], although some of these
diacylated lipopeptides can also induce signaling in the ab-
sence of TLR-6 [35]. We also tested zymosan, a β-glucan
present in yeast cell wall, which uses the Dectin-1/TLR-2
complex as receptor [33]. Finally, we tested lipoarabi-
domannan of Mycobacterium smegmatis (LAM-MS) and
polysaccharide A of Bacteroides fragilis (PSA). These last
two have been shown to induce signaling mainly through
TLR-2 alone [36,37]. As shown in Figure 1B, the TLR-1/2
agonist Pam3CSK4 was the only TLR-2 agonist able to in-
duce reactivation of latent HIV-1 in cultured TCM.W ec o n -
firmed the activities of all TLR-2 agonists to induce IL-8
production in THP-1 cells (Additional file 2: Figure S2B).
Furthermore, Zymosan behaved as a strong inductor of
HIV-1 expression in the cell line J-LAT 10.6 (Additional
file 2: Figure S2A). Finally,P a m 3 C S K 4 ,P a m 2 C S K 4a n d
Zymosan were able to reactivate latent HIV-1 in the U1
cell line (Additional file 2: Figure S2C). These results sug-
gest that signaling through TLR-2/TLR-1 complexes, but
not other TLR-2-containing complexes, are able to reacti-
vate latent HIV-1 in cultured TCM. Thus, we conclude that
signals that use TLR-2 alone or TLR-2 in combination with
TLR-6 or Dectin-1 are not sufficient to reactivate latent
HIV-1 in cultured TCM.
We next decided to analyze the expression levels of
TLR-1 and TLR-2 in cultured TCM and in ex vivo
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+ T cells from healthy donors. As
shown in Figure 1C, we detected surface expression of
both, TLR-1 and TLR-2, in cultured TCM. Also, both
receptors were expressed comparably in the three main
subsets of memory CD4
+ T cells, namely TCM,T TM and
TEM (Figure 1D).
To further confirm whether Pam3CSK4 was able to re-
activate latent HIV-1 ex vivo, we performed two different
assays using resting CD4
+ T cells from aviremic patients.
In the first one, cells were treated with IL-2, IL-2 plus
Pam3CSK4 or IL-2 plus panobinostat, an HDAC inhibi-
tor that has been shown to reactivate latent HIV-1 [38].
Three days after treatment, intracellular HIV-1 unspliced
mRNA was quantified by RT-PCR. As shown in Figure 1E,
Pam3CSK4 increased the levels of US-RNA over IL-2
treatment control in 2 of the 7 patients compared with
5 of 7 for panobinostat. In one of the patients, neither
Pam3CSK4 nor panobinostat was able to reactivate latent
HIV over IL-2 control (Figure 1E, closed start symbol). In
the second assay, cells from 4 aviremic patients were sub-
jected to the quantitative viral outgrowth assay (Q-VOA)
assay [39,40]. In this case, exposure to Pam3CSK4 allowed
recovery of replication competent virus from resting CD4
+
T cells of 2 ART-suppressed patients, although, as is gen-
erally seen with HDAC inhibitors, the frequency of induc-
tion of HIV outgrowth was greater after cells were fully
activated by mitogen (Figure 1F). In the fourth patient, the
frequency of latent infection was very low (less than 1 in-
fected cell in 5 million resting CD4
+ Tcells), and the activ-
ity of Pam3CSK4 could not be assessed.
Pam3CSK4 induces viral reactivation through the activation
of NFκB, NFAT and AP-1 transcription factors
We decided to investigate the signaling pathway that
leads to viral reactivation mediated by Pam3CSK4 in cul-
tured TCM. First, we analyzed the cis-acting elements in
the viral long-terminal repeat (LTR) required for viral re-
activation induced by Pam3CSK4 and compared them with
those required for αCD3/αCD28. This was accomplished
by generating defective (env-) HIV mutants with nucleotide
substitutions in the binding sites for NFκB/NFAT, Sp1 or
NF-IL6 as previously described [24]. As shown in
Figure 2A, mutation of the three binding sites for Sp1 ab-
rogated viral reactivation mediated by Pam3CSK4 and by
αCD3/αCD28. Mutation of both NFκB binding elements
impaired the reactivation by Pam3CSK4 by 80% on aver-
age. Interestingly, in one of the three donors, mutation of
NFκB binding sites did not disrupt viral reactivation by
αCD3/αCD28. This result suggests that other transcription
factor binding sites may bypass the presence of intact
NFκB/NFAT binding sites in viral reactivation mediated by
αCD3/αCD28, as it has been previously described [41].
When cells were infected with a virus containing mutations
in the NFκB/NFATand Sp1 binding sites, viral reactivation
induced by both stimuli was also almost completely abro-
gated. As a control, we mutated both NF-IL6 binding sites
and showed that mutation in these cis-acting elements had
almost no effect on viral reactivation driven by Pam3CSK4
and αCD3/αCD28. These results indicate that efficient
Pam3CSK4-induced viral reactivation requires the pres-
ence of intact NFκB/NFAT and/or Sp1 binding sites on
the LTR.
To further characterize the signaling pathway that
leads to viral reactivation induced by Pam3CSK4 in cul-
tured TCM, we used chemical inhibitors of known signal-
ing pathways activated by TLRs. It is known that TLR-1/2
activates NFκB via MyD88 and the subsequent formation
of a complex with IRAK1/IRAK4 and TRAF6. This com-
plex leads to the activation of the IKK complex through
the kinase TAK1 and the phosphorylation and degradation
of IκBα leading to the activation and translocation to the
nucleus of NFκB [22]. To assess the role of NFκB in viral
reactivation induced by Pam3CSK4, we incubated cells
with BAY 11–7082, an inhibitor of IκBα phosphorylation.
As shown in Figure 2B, BAY 11–7082 blocked an average
of 60% of viral reactivation induced by Pam3CSK4. How-
ever, BAY 11–7082 had a minor inhibitory effect (less than
20% inhibition on average) on viral reactivation induced
(See figure on previous page.)
Figure 1 Reactivation of latent HIV-1 through toll-like receptors agonists. (A) Cultured TCM were treated with the toll-like receptors agonists
indicated between parentheses for different TLRs or costimulated with αCD3/αCD28 and assessed for intracellular p24Gag expression by flow
cytometry. Experiments were done in 5 different donors. Each dot represents a different donor and mean and SD are indicated with horizontal
lines. Significance was calculated by 2-tailed paired samples t test analysis (P vales provided). (B) Cultured TCM were treated with different TLR-2
agonists indicated between parentheses or costimulated with αCD3/αCD28 and assessed for intracellular p24Gag expression by flow cytometry.
Experiments were done in 3 donors from A. Significance was calculated by 2-tailed paired samples t test analysis (P vales provided).
(C) Cultured TCM were stained with specific antibodies against TLR-1 and TLR-2 (open black histogram) and analyzed by flow cytometry. Isotype
controls were used as control (closed grey histogram). The percentage of TLR-1 and TLR-2 positive cells is indicated in each panel. (D) Ex vivo
isolated memory CD4
+ T cells were stained with specific antibodies against CCR7, CD27, TLR-1 and TLR-2 and analyzed by flow cytometry.
Expression of TLR-1 and TLR-2 was analyzed in each subset of memory CD4
+ T cells (open black histogram). Isotype controls were used as control
(closed grey histogram). The percentage of TLR-1 and TLR-2 positive cells in each subset is indicated in each panel. (E) Cells isolated from seven
aviremic patients were treated with Pam3CSK4 or Panobinostat and the levels of HIV-1 US RNA were measured three days later. Each symbol
corresponds to a different patient. Data is represented as fold induction over the IL-2 treatment control (F) Cells isolated from three aviremic
patients were treated with IL-2, Pam3CSK4 or PHA for 24 hours and supernatants were subject to the Q-VOA assay.
Novis et al. Retrovirology 2013, 10:119 Page 4 of 15
http://www.retrovirology.com/content/10/1/119by αCD3/αCD28 (Figure 2B). This result is in agreement
with our previous studies indicating an unexpected lack
of requirement for NFκB toward viral reactivation after
stimulation with αCD3/αCD28 [24]. However, in a sig-
naling pathway other than αCD3/αCD28, we showed that
NFκB was active and required for reactivating latent
viruses in a stimulus-dependent manner in cultured
TCM.
MyD88 activation also leads to the activation of the
MAP kinase cascade, in particular JNK and ERK-1/2,
which leads to the activation of the transcription factor
AP-1. Cooperation between these transcription factors,
NFκB and AP-1, has been shown to transactivate the
HIV-1 LTR in cells lines [42,43]. To investigate the role
of AP-1 in viral reactivation induced by Pam3CSK4, we
incubated the cells with SP600125 or PD98059, known
Figure 2 Pam3CSK4 requires NFAT, AP-1 and NF-κB to induce viral reactivation in cultured TCM. (A) Cultured TCM cells were infected with
wild-type DHIV or with different LTR mutants. 9 days after infection, cells were treated with Pam3CSK4 or costimulated with antibodies to CD3
and CD28 (αCD3/αCD28) for 3 days and assessed for intracellular p24Gag expression by flow cytometry. Percentage of reactivation was
normalized to that of wild-type DHIV for each treatment. Bar graph corresponds to mean and SD of experiments performed with three donors.
(B) Cultured TCM cells were infected with wild-type DHIV and treated with Pam3CSK4 or stimulated with αCD3/αCD28 in the presence of the
indicated inhibitor for the protein or transcription factor indicated and assessed for intracellular p24 Gag expression by flow cytometry. Bar graph
corresponds to mean and SD of experiments performed with four different donors. Significance was calculated by 2-tailed paired samples t test
analysis (*< 0.05, **< 0.01, ***<0.001).
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shown in Figure 2B, both inhibitors significantly abro-
gated viral reactivation by Pam3CSK4.
We have previously shown that NFAT is required for
viral reactivation mediated by αCD3/αCD28 in cultured
TCM [24]. In agreement with that finding, Cyclosporine
A (CsA), a potent NFAT inhibitor, blocked viral reactiva-
tion induced with αCD3/αCD28 (Figure 2B). Interestingly,
CsA was able to impair viral reactivation mediated by
Pam3CSK4 by 55% on average. These data suggest NFAT
is also required for viral reactivation downstream of
Pam3CSK4.
In an effort to validate the experiments performed with
chemical inhibitors, we investigated whether Pam3CSK4
could induce nuclear translocation of NFκB, NFAT and
AP-1 in cultured TCM in a time-dependent manner. To
that end, we isolated cytoplasmic and nuclear fractions
after stimulating with IL-2 alone (baseline condition),
Pam3CSK4 or αCD3/αCD28. We isolated fractions of cul-
tured TCM that were unstimulated; after 30 minutes
of stimulation; or 3 hours of stimulation. The trans-
location of the different transcription factors was analyzed
by Western-blot. α-tubulin and histone H3 proteins were
used as controls for purity of the fractionation and β-actin
was used as a loading control. As shown in Figure 3A, p50
was detected in the nucleus after 30 minutes of incubation
with Pam3CSK4 (compare lanes 8 and 11) but not with
IL-2 alone (compare lane 8 with 9 and 10) or αCD3/
αCD28 (compare lane 8 with 13 and 14) but decreased
to basal level by 3 hours of stimulation. In the case of
p65, increased nuclear levels could be detected after treat-
ment of the cells with Pam3CSK4 at 30 min and 3 hours
post-reactivation (lanes 11 and 12 compared with lane 8).
Interestingly, both Pam3CSK4 and αCD3/αCD28 induced
the nuclear translocation of NFATc1, which was detectable
a t3 0m i na n d3h o u r s( F i g u r e3 A ,l a n e s1 1t o1 4c o m p a r e d
with lane 8). We also detected a strong nuclear transloca-
tion of NFATc2 when cells were reactivated with αCD3/
αCD28 (lanes 13 and 14 compared with lane 8). Nuclear
translocation of NFATc2 was also detected after treatment
of the cells with Pam3CSK4 but at a much smaller magni-
tude (lanes 11 and 12 compared with lane 8).
We have previously shown that JNK and ERK inhibi-
tors blocked viral reactivation mediated by Pam3CSK4
(Figure 2B). JNK and ERK are involved in the activation re-
spectively of cJun and cFos, components of the transcrip-
tion factor AP-1. As shown in Figure 3B, we detected
nuclear translocation of cJun at 3 hours with either IL-2,
Pam3CSK4 or αCD3/αCD28 stimulation (lanes 10, 12 and
14 compared with lane 8). The levels of nuclear transloca-
tion were slightly higher with Pam3CSK4 than with IL-2
alone (Figure 3B, compare lanes 10 and 12). Surprisingly,
we were unable to detect nuclear translocation of cFos at
any time with either IL-2 or Pam3CSK4 (Figure 3B, lanes 9
to 12). The inability to detect efficient nuclear translocation
of cFos and cJun with Pam3CSK4 may be due to the low
sensitivity of the assay. For this reason, we decided to
analyze whether Pam3CSK4 could activate JNK and ERK.
As shown in Figure 3C, treatment with Pam3CSK4 re-
sulted in increased JNK and ERK phosphorylation (lane 5)
above what was observed with IL-2 alone (lane 2). These
results suggest than Pam3CSK4 can efficiently induce
NFκB and NFAT translocation into the nucleus. Further-
more, Pam3CSK4 induces activation of the JNK and ERK
pathways required for AP-1 activation.
Pam3CSK4 but not other TLR2 agonist triggers intracellular
Ca
2+ influx
We found that NFAT was translocated into the nucleus
after challenging cultured TCM with Pam3CSK4. NFAT ac-
tivation is induced after dephosphorylation mediated by the
Ca
2+/calmodulin-dependent serine phosphatase calcine-
urin, which is activated after an increase in the levels of
intracellular Ca
2+.T h e r e f o r e ,w ei n f e r r e dt h a tN F A Ta c t i v a -
tion by Pam3CSK4 is a consequence of an increase in the
intracellular levels of Ca
2+. To test this idea, cultured TCM
were loaded with Fluo3-AM, a fluorescent indicator of
intracellular Ca
2+, and changes in intracellular levels were
measured by flow cytometry. We incubated cells with the
ionophore ionomycin (positive control), or the TLR-2 ago-
nists Pam3CSK4, Pam2CSK4 or LAM-MS. As expected,
ionomycin induced an increase in the intracellular levels of
Ca
2+ (Figure 4). When cells were treated with Pam3CSK4,
we observed an increase in the intracellular levels of Ca
2+
in a dose dependent manner. However, this increase in cal-
cium levels was not observed after treatment with the non-
HIV reactivating agents Pam2CSK4 or LAM-MS.
Taken together, these data suggest that Pam3CSK4 in-
creases intracellular Ca
2+ flux, which is consistent with
NFAT nuclear translocation and its role on HIV-1 reactiva-
tion mediated by Pam3CSK4. Furthermore, the inability of
Pam2CSK4 and LAM-MS to increase intracellular Ca
2+
may explain their failure to transactivate the HIV-1 LTR
(Figure 1B).
Pam3CSK4 reactivates HIV-1 in a tat-dependent manner
but in the absence of upregulation of cyclin T1
Tat is a viral transactivator necessary for the HIV-1 pro-
moter to achieve maximal levels of activity. We therefore
examined whether reactivation by Pam3CSK4 is Tat
dependent. Tat recruits the positive transcription elong-
ation factor pTEFb, a protein kinase complex that con-
sists of Cyclin T1 and CDK9, to the TAR (trans acting
response element) RNA located at the 5′ end of viral
transcripts [46]. pTEFb is responsible for hyperphosphor-
ylation of the C-terminal domain of RNA Pol II and evic-
tion of negative elongation factors, which culminates in
transcription activation [47-49]. We used Flavopiridol, a
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http://www.retrovirology.com/content/10/1/119Figure 3 Signaling triggered by Pam3CSK4 in cultured TCM. Culture TCM were either left unstimulated (0 h) or stimulated with IL-2,
Pam3CSK4 and αCD3/αCD28 after 30 minutes or 3 hours. Nuclear and cytoplasmic fractions were isolated as indicated in the experimental
procedure section. Proteins were loaded on a SDS-polyacrylamide gel, transferred to a membrane and western-blotted against p50, p65, NFATc1,
NFATc2, α-tubulin, histone H3 and β-actin (A) or against cJun, cFos, histone H3 and β-actin (B). Data is representative of two donors. (C) Culture
TCM were left unstimulated (0 h) or stimulated with IL-2, Pam3CSK4 and αCD3/αCD28 after 30 minutes or 3 hours. Whole cell extracts were
isolated as indicated in the experimental procedure section. Proteins were loaded on a SDS-polyacrylamide gel, transferred to a membrane and
western-blotted against JNK, phospho-JNK, ERK, phospho-ERK and β-actin. Data is representative of two donors.
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involved in viral reactivation mediated by Pam3CSK4. As
shown in Figure 5A, flavopiridol blocked viral reactivation
mediated by Pam3CSK4 and by αCD3/αCD28 in a dose
dependent manner (Figure 5A).
Low levels of the pTEFb main components, cyclin T1
and pCDK9, have been proposed to limit the ability of the
LTR to efficiently drive transcription in resting cells [50].
We analyzed whether Pam3CSK4 induced an increase in
the levels of cyclin T1 or in the phosphorylation levels of
CDK9 in cultured TCM. As shown in Figure 5B, levels of
cyclin T1 remained constant when cells were incubated
with IL-2 alone or in the presence of Pam3CSK4 (lanes 1
to 7). In contrast, incubation with αCD3/αCD28 increased
the total levels of cyclin T1 in culture TCM as previously
described (lines 8 to 10) [50]. We then analyzed the
levels of CDK9 and pCDK9. It has been previously
shown that CDK9 exists in two isoforms generated
from two different promoters [51]. Both isoforms can
be found as part of pTEFb complexes [51]. As shown
in Figure 5B, cultured TCM express both isoforms and
the total levels of each isoform of CDK9 (CDK955 and
CDK942 as indicated in Figure 5B) did not change with
any of the treatments. Levels of pCDK955 were drasti-
cally increased when cells were incubated with αCD3/
αCD28 (Compare lanes 1 to 8 and 9). Pam3SCK4 was able
to increase levels of pCDK955 at 12 h when compare with
IL-2 treatment alone (Figure 5B, lines 2 and 5). These re-
sults indicate that Pam3CSK4 reactivates latent HIV in a
pTEFb dependent manner but in the absence of cyclinT1
upregulation.
Pam3CSK4 reactivates latent HIV-1 in the absence of T cell
activation and/or proliferation
We have shown that stimulation through CD3 and CD28
or Pam3CSK4 leads to viral reactivation through the ac-
tivation of different transcription factors. It is well
known that activation through CD3 and CD28 leads to
global T cell activation encompassing release of cytokines
and chemokines, massive T cell proliferation and can lead
to durable T cell depletion in HIV-infected patients [52,53].
To test whether Pam3CSK4 triggers global T cell activation
in cultured TCM, we assessed the induction of CD69 and
CD25. As shown in Figure 6A, Pam3CSK4 failed to induce
up regulation of CD69 when compared with stimulation
with IL-2 alone (baseline condition). As expected, αCD3/
αCD28 stimulation strongly induced up-regulation of the
activation marker. We have previously shown that cultured
TCM and ex vivo isolated TCM show low levels of CD25
protein expression on the surface and the expression is
up-regulated after TCR engagement [54]. As shown in
Figure 6B, Pam3CSK4 did not up-regulate the expression
levels of CD25 when compared with stimulation with IL-2
alone (baseline condition). However, treatment of cultured
Figure 4 Pam3CSK4 triggers intracellular Ca
2+ influx. Cultured TCM were loaded with the Ca
2+ dye Fluo3-AM and cells were tested for their
ability to increase intracellular calcium levels after treatment with ionomycin, or with increasing concentrations of Pam3CSK4, Pam2CSK4 or LAM-MSb y
flow cytometry. The arrows indicate when the stimuli were added. Data is representative of two donors.
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activation marker (63 times increased MFI compared with
IL-2 treatment alone).
Using this in vitro model, we have previously shown
that IL-7 plus IL-2 can induce a low degree of viral re-
activation in the presence of cellular proliferation [54].
Cellular proliferation in the absence of viral reactivation has
been proposed as a mechanism for maintenance of the la-
tent reservoir [5,54]. To address whether Pam3CSK4 was
able to induce cellular proliferation, we stained cells with
the cell proliferation dye CPD eFluor647. After staining,
cells were incubated with IL-2 alone, Pam3CSK4 or αCD3/
αCD28 and cellular proliferation and viral reactivation was
measured 3 days later. As shown in Figure 6C, Pam3CSK4
induced viral reactivation in the absence of cellular proli-
feration when compared with our control treatment of IL-2
alone. However, reactivation through CD3 and CD28 led to
massive cellular proliferation as well as viral reactivation
Figure 5 Pam3CSK4 induces viral reactivation in a Tat-dependent manner. (A) Cultured TCM cells were infected with wild-type DHIV and
treated with Pam3CSK4 or stimulated with αCD3/αCD28 in the presence of 50 nM and 100 nM of Flavopiridol and assessed for intracellular p24
Gag expression by flow cytometry. Data is representative of two donors. (B) Culture TCM were either left unstimulated (0 h) or stimulated
with IL-2, Pam3CSK4 and αCD3/αCD28 for 12 h, 24 h or 48 h. Whole cell extracts were isolated as indicated in the experimental procedure
section. Proteins were loaded on a SDS-polyacrylamide gel, transferred to a membrane and western-blotted against CyclinT1, phospho-CDK9,
CDK9, and β-actin. Data is representative of two donors.
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reactivate latent HIV-1 in the absence of T cell activation
or proliferation.
Discussion
In this study, we have found that Pam3CSK4, a TLR-1/2
agonist, is able to reactivate HIV-1 from latency in
primary cultured TCM cells. We have also tested the abi-
lity of Pam3CSK4 to reactivate latent HIV-1 in two
ex vivo models. In this case, Pam3CSK4 is able to reacti-
vate latent HIV-1 in a fraction of the patients. Several
polymorphisms have been described to affect TLR-1/2
signaling [55-57]. It will be interesting to address whether
these polymorphisms are associated with the ability of
Figure 6 Pam3CSK4 induces viral reactivation in the absence of T cell activation or T cell proliferation. Cultured TCM cells were treated with IL-2,
Pam3CSK4 or costimulated with antibodies to CD3 and CD28 (αCD3/αCD28) for 3 days and assessed for the induction of CD69 (A) and CD25 (B) by
flow cytometry (open black histograms). Isotype control was used as control (closed gray histogram). The percentage of CD69 and CD25 positive cells is
indicated in each panel and the mean fluorescence intensity (MFI) is indicated between parentheses for CD25. Data is representative of three donors.
(C) Cultured TCM cells were infected with wild-type DHIV or left uninfected. At 9 days after infection, cells were stained with the cell-proliferation dye CPD
eFluor670. Stained cells were treated with IL-2, Pam3CSK4 or costimulated with antibodies to CD3 and CD28 (αCD3/αCD28) for 3 days and assessed for
intracellular p24Gag expression and CPD eFluor670 staining by flow cytometry. Numbers indicate percentage of cells. Data is representative of three donors.
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+
Tcells.
Several PAMPs and their corresponding microorganisms
have been shown to directly transactivate the HIV-1 LTR.
Live mycobacteria as well as some of their components in-
duce HIV-1 expression in human monocytes, lymphocytes,
or cell lines in vitro [58-62]. This induction has been
shown to be dependent on TLR-2 [62,63]. Flagellin, a
TLR-5 agonist, reactivates latent HIV-1 in the cell line
J-Lat [28]. Furthermore, the TLR-7/8 agonist, R-848, is able
to reactivate latent HIV-1 from myeloid-monocytic cells
lines [64]. Finally, the TLR-9 agonist, CpG oligodeoxynu-
cleotide, has been shown to reactivate latent HIV-1 in the
cell line ACH-2 [29]. In an independent study, performed
while this work was in progress, Dr. Jonathan Karn and
colleagues have found that TLR-5 agonist flagellin leads to
viral reactivation from latency in microglial cells, and that
the TLR-3 and TLR-9 agonist, poly (I:C) and ODN2006 re-
spectively, weakly reactivate latent HIV-1 in a primary cell
model of TH17 cells (manuscript in preparation).
TLR-2 recognizes a wide range of ligands because it
functions in conjunction with other receptors [65]. Thus,
TLR-2 can form heterodimers with TLR-1 or TLR-6.
TLR-1/2 complexes recognize triacylated lipopeptides
whereas TLR-2/6 complexes recognize diacylated lipo-
peptides [34,66]. In addition, TLR-2 has been shown to
cooperate with TLR-10 [32] and with the c-type lectin,
Dectin-1 [33]. We have shown that the triacylated lipo-
peptide Pam3CSK4 is the only TLR-2 agonist tested able
to induce viral reactivation. Interestingly, Pam3CSK4 was
able to induce an increase in intracellular calcium and
subsequent activation of the transcription factor NFAT.
We have shown that, in addition to the canonical pathway
of NFκB and AP1 activation mediated by TLR-1/2, NFAT
activation is also required for viral reactivation. Our result
is in agreement with a published report showing that
Pam3CSK4 stimulates release of Ca
2+ from intracellular
stores in lung fibroblast [67] and with several reports
showing activation of NFAT after stimulation of bone
marrow-derived macrophages with Pam3CSK4, zymosan
and other TLR agonists [68,69]. To our knowledge, this is
the first time that it has been reported that Pam3CSK4
can activate NFAT in human primary CD4
+ Tcells.
We have previously demonstrated that NFAT but not
NFκB plays a major role in viral reactivation through
αCD3/αCD28 in cultured TCM (this report and [24]). On
the other hand, stimulation with the TLR-1/2 agonist
Pam3CSK4 leads to the activation of both NFκB and
NFAT and both transcription factors are involved in viral
reactivation mediated by Pam3CSK4. These results sug-
gest that HIV-1 has evolved to use different transcrip-
tion factors to increase viral transcription and that the
ability of NFAT or NFκB to induce viral transcription is
not determined by the viral LTR but by the stimulus.
It is well known that stimulation through CD3 and
CD28 leads to large-scale T cell activation, release of cy-
tokines and chemokines, massive T cell proliferation and
ultimately leads to profound T cell depletion in humans
[52,53]. However, we show here that Pam3CSK4 is able
to activate the HIV-1 promoter in a NFκB and NFAT-
dependent manner; but it does so in the absence of overt
signs of T cell activation, specifically, CD69, CD25 and T
cell proliferation. We have identified several differences
between the signaling pathways activated by αCD3/
αCD28 and Pam3CSK4 that can account for the differ-
ence in T cell activation. First, αCD3/αCD28 induced a
stronger nuclear translocation of the constitutive NFAT
isoform NFATc2 and a better activation of the transcrip-
tion factor AP-1. Both, AP-1 and NFAT form a quater-
nary complex during T-cell activation [70]. Second,
Pam3CSK4 is a more potent inductor of NFκB relative
to αCD3/αCD28. Third, Pam3CSK4 does not increase
the levels of cyclin T1 and induces low levels of pCDK9
whereas αCD3/αCD28 induce a strong increase of both,
cyclin T1 and pCDK9. These results demonstrate that
viral reactivation and cellular activation can be effectively
decoupled. Also, these differences can have implications
in the search for molecules that efficiently and safely re-
activate latent HIV-1 virus in the absence of massive T
cell activation. We hypothesized that those molecules
that specifically activate NFκB, NFATc1, a weak AP-1
and do not upregulate cyclin T1 will be more desirable as
anti-latency drugs than substances that induce a strong
NFATc2, AP-1, cyclin T1 and pCDK9 responses.
Conclusion
Our results show that Pam3CSK4 has the potential to
reactivate latent HIV-1 in TCM. These findings raise a
series of important questions for further study: can
Pam3CSK4 or other TLR agonists reactivate latent HIV
in other primary cell models; are NFAT, NFκB and AP-1
recruited to the LTR following Pam3CSK4 signaling;
why is the response to Pam3CSK4 heterogeneous in cells
isolated from patients? As agents that can induce the ex-
pression of latent HIV without mediating global T cell
activation are uncommon but highly valuable as poten-
tial drugs to attack the latent HIV reservoir, further
study and testing of Pam3CSK4 and its signaling path-
way is a high priority.
Although PAMPs are normally associated with infec-
tious agents, their ability to enhance immune responses
was documented in the context of cancer therapy a cen-
tury ago, when William Coley used bacterial components
named “Coley’st o x i n s ” to treat cancer patients [71]. Since
then, several TLR agonists have been investigated for the
use in treatment of cancer; viral or bacterial infections; al-
lergy; asthma and autoimmunity (reviewed in [72]). In par-
ticular the triacylated lipopeptide outer surface protein A
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agonist, has been previously clinically used as a vaccine
against Lyme disease with minor side effects (reviewed in
[73]). We suggest that triacylated lipopeptides and/or the
TLR-1/2 signaling pathway can be targeted toward future
development of anti-latency strategies, either alone or in
combination with others anti-latency drugs.
Methods
Reagents
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID: Human rIL-2 from Dr. Maurice Gately,
Hoffman-La Roche Inc. [74]; Monoclonal Antibody to
HIV-1 p24 (AG3.0) from Dr. Jonathan Allan [75]; and
Flavopiridol.
Generation of cultured TCM cells and their latent infection
Naïve CD4
+ T cells were isolated via negative selection
from peripheral blood mononuclear cells (PBMC) from
healthy unidentified donors 18 years and older. Written
informed consent was obtained from all donors. These
studies are covered under the IRB #392 protocol ap-
proved by the University of Utah Institutional Review




5 cells were left untreated or stimulated for three
days with the PRR agonists or beads coated with αCD3
and αCD28 (1 bead per cell, Dynal/Invitrogen, Carlsbad,
CA). PRR agonists were obtained from Invivogen (San
Diego, CA) and used at the concentration indicated:
Pam3CSK4 (10 μg/ml), Pam2CSK4 (200 ng/ml), FSL-1
(10 μg/ml), Poly (I:C) HMW (10 μg/ml), LPS (10 μg/ml),
flagellin (10 μg/ml), imiquimod (10 μg/ml), ssRNA40
(5 μg/ml), ODN2006 (5 μM), zymosan (200 μg/ml)
and lipoarabinomannan from Mycobacterium smegmatis
(LAM-MS) (10 μg/ml). TLR-2 agonist polysaccharide-A
(PSA) was kindly provided by June Round (Pathology
Department, University of Utah).
For inhibitors studies, cells were pre-incubated with
the indicated inhibitors for 2 hours before stimulation.
The inhibitors used were 1 μg/ml Cyclosporine-A (Sigma-
Aldrich, Saint Louis, MO); 0.8 μM BAY 11-7082 and
50 μM PD98059 (Calbiochem, San Diego, CA); 25 μM
SP600125 (A.G. Scientific Int., San Diego, CA); 50 nM and
100nM Flavopiridol (AIDS Research and Reference Re-
agent Program, Division of AIDS, NIAID).
Ex-vivo HIV-1 RNA reactivation assay
Frozen cells from 7 HIV-infected patients receiving
HAART with plasma viral load <50 copies/ml for at least
6 months and CD4 count of >350 ul
-1 were used for the
ex-vivo HIV-1 RNA reactivation assay. A median of
50×10
6 frozen PBMCs were used to isolate CD4
+ T cells
using CD4
+ T cell isolation kit (Milteny Biotec). CD4
+
T cells were incubated in media containing 10 ug/ml
Pam3CSK4 and 30 IU/ml IL-2, or 1uM Panobinostat
and 30 U/ml IL-2. A background control well was set
up with media supplemented with 30 U/ml IL-2. After
72 hours, total RNA was extracted and cDNA synthe-
sized. Unspliced HIV-1 RNA was quantified by real-time
PCR, using primers and probes previously described [76].
Data were normalized to the expression of the house-
keeping gene Actb (encoding b-actin). Results were
plotted as a fold change induction of HIV-1 RNA ex-
pression between the test well and the background
control well.
Quantitative viral outgrowth assay (Q-VOA)
Outgrowth assays were performed, as described previ-
ously [39]. Briefly, PBMC were obtained by continuous-
flow leukapheresis from HIV-infected volunteers re-
ceiving stable ART with plasma HIV-1 RNA less than
50 copies/ml and a CD4
+ Tc e l lc o u n to fm o r et h a n
300 cells/ml. Resting CD4
+ T cells were isolated by nega-
tive selection from PBMC and incubated in limiting
dilutions with Pam3CSK4 or IL-2 for 24–48 hours or
maximally stimulated with PHA-L, allogeneic irradiated
PBMC from a sero-negative donor, and rIL-2. Cultures
were fed twice with CD8-depleted PBMC, collected from
a CCR5 high sero-negative donor. Supernatant was col-
lected on days 15 and 19 and HIV p24 Gag antigen was
measured by ELISA. Cultures that maintained an equiva-
lent or greater level of p24 antigen on day 19 as on day
15 were scored as positive. A maximum likelihood method




Intracellular p24 Gag expression was analyzed as previ-
ously described [24].
Surface expression was determined using anti-human
CD281-PE (TLR-1, clone GD2.F4, eBioscience, San
Diego, CA), anti-human CD282-PE (TLR-2, clone TL2.1,
eBioscience, San Diego, CA), anti-human CD25-FITC
(Molecular Probes, Eugene, OR), anti-human CD69-FITC
(Molecular Probes, Eugene, OR), anti-human CCR7-APC
(R&D Systems, Minneapolis, MN) and anti-human CD27-
FITC (Molecular Probes, Eugene, OR)
To analyze cell division with Cell Proliferation Dye
eFluor 670 (eBioscience, San Diego, CA), cells were
stained as indicated by the manufacturer.
Flow cytometry was performed with a BD FacsCanto II
flow cytometer using the FACSDiva software (Becton
Dickinson, Mountain View, CA). Data was analyzed with
FlowJo (TreeStar Inc, Ashland, OR).
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Cells were loaded using Fluo-3 AM (Molecular Probes,
Eugene, OR) following manufacturer’s protocol and ana-
lyzed by flow cytometry. Cells were left at room temperature
in the dark, for 15 minutes. A 20 seconds baseline was
recorded prior to addition of the stimulus. After addition
of the stimulus cells were vortexed and analysis was
performed during additional 150 seconds. 20 ng/ml of
Ionomycin was used as a positive control.
Western blotting
To analyze phosphorylation, five million cultured TCM
were lysed using a lysis buffer containing 50 mM Tris–HCl
[pH 8], 150 mM NaCl, 1% NP-40, and 0.1% protease and
phosphatase inhibitors (Roche Diagnostics, Indianapolis,
IN) for 30 minutes at 4°C. Lysates were cleared by centrifu-
gation at 12000 rpm for 20 min at 4C.
To analyze nuclear translocation, five million cultured
TCM cells were washed in PBS and incubated with a cell
lysis buffer containing 5 nM PIPES [pH8], 85 mM KCl,
0.5% NP-40 and 0.1% protease and phosphatase inhibi-
tors for 30 min. After incubation, nuclei were pelleted
by centrifugation at 5000 rpm during 20 min at 4°C. Su-
pernatants were collected as cytoplasmic fractions. Nuclei
were washed once with PBS containing 0.1% protease and
phosphatase inhibitors and pelleted by centrifugation at
5000 rpm during 20 min at 4C. Nuclei were lysed with a
buffer containing 50 mM Tris [pH 8.1], 10 nM EDTA, 1%
SDS and 0.1% protease and phosphatase inhibitors and
boiled for 10 min at 100°C. Nuclear extracts were cleared
by centrifugation at 12000 rpm for 10 min at RT.
Proteins were separated on SDS-PAGE electrophoresis.
Western blotting was performed according to the standard
protocols. The following antibodies were used: p50, p65,
NFATc1, NFATc2, cJun, cFos and cyclin-T1 (Santa Cruz
Biotechnology, Santa Cruz, CA); total JNK, pJNK, total
ERK, pERK, total CDK9 and pCDK9 (Cell Signaling,
Danvers, MA); anti-β-actin antibody (Sigma-Aldrich, Saint
Louis, MO); anti-α-tubulin antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) and anti-histone H3 (Biolegend,
San Diego, CA).
Additional methods provided in Additional file 3.
Additional files
Additional file 1: Figure S1. Effects of TLR agonists in four cellular
models. (A) J-Lat 10.6 cells were treated with the toll-like receptors agonists
indicated between parentheses or PMA and assessed for GFP expression by
flow cytometry. (B) THP-1 cells were treated with the toll-like receptors
agonists indicated between parentheses or PMA and assessed for IL-8
expression by flow cytometry. (C) U1 cells were treated with the toll-like
receptors agonists indicated between parentheses or PMA and assessed for
intracellular p24 expression by flow cytometry. (D) ACH-2 cells were treated
with the toll-like receptors agonists indicated between parentheses or PMA
and assessed for intracellular p24 expression by flow cytometry.
Additional file 2: Figure S2. Effects of TLR-2 agonists in four cellular
models. (A) J-Lat 10.6 cells were treated with the TLR-2 agonists indicated
between parentheses or PMA and assessed for GFP expression by flow
cytometry. (B) THP-1 cells were treated with the TLR-2 agonists indicated
between parentheses or PMA and assessed for IL-8 expression by flow
cytometry. (C) U1 cells were treated with the TLR-2 agonists indicated
between parentheses or PMA and assessed for intracellular p24 expression
by flow cytometry. (D) ACH-2 cells were treated with the TLR-2 agonists
indicated between parentheses or PMA and assessed for intracellular p24
expression by flow cytometry.
Additional file 3: Supplemental Methods.
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